Understanding the Role of MR Antagonists and the Impact on Patient Care in CKD in T2D

Join us for an interactive live symposium discussing the use of finerenone in patients with type 2 diabetes and chronic kidney disease.  Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP and Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP will provide expert insights on the evidence behind the use of finerenone in diabetic kidney disease, selecting appropriate patients for finerenone therapy, and strategies for overcoming clinical inertia.

ProCE is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. Additionally, in accordance with APhA’s COVID-19 protocols, all in-person learners will be asked to wear a mask and present their APhA conference badge -OR- proof of vaccination AND Government issued ID to gain admittance to Understanding the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in Chronic Kidney Disease in Type 2 Diabetes and/or Digital Technologies in Diabetes Management: Considerations for Delivering State-of-the-Art Care.

For more information on APhA’s vaccination and mask requirements, please visit: https://aphameeting.pharmacist.com/aaStatic.asp?SFP=WkpaSkJNQkdAOTI4Ng

*If you do not have your vaccination record card, find out other ways to verify you have been vaccinated.

Agenda

*All times are listed in local time zone (CT)

6:00 AM – 6:30 AM Registration

6:30 AM – 6:35 AM Welcome and Opening Remarks

6:35 AM – 6:55 AM Overview of CKD in T2D

6:55 AM – 7:15 AM MR Blockade to Treat T2D-Associated CKD

7:15 AM – 7:45 AM Patient Selection, Multidisciplinary Care, and Overcoming Clinical Inertia

7:45 AM – 8:00 AM Question and Answer Session

Events

Date / Time
Event Details

Faculty

Faculty
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP

Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator

Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio

Faculty
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice-Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington

Program Overview
The program will provide an overview of CKD in type 2 diabetes, and expert insights on the evidence behind the use of finerenone in diabetic kidney disease, selecting appropriate patients for finerenone therapy, and strategies for overcoming clinical inertia.

Goal Statement
The goal of this activity is to improve the knowledge and competence of pharmacists about pathophysiology of mineralocorticoid receptor activation in CKD in patients with T2D and the impact of the selective nonsteroidal mineralocorticoid receptor antagonist finerenone on patient care.

Target Audience
The target audience for this activity is pharmacists, including community, ambulatory care, primary care, and clinical pharmacists, who care for patients with CKD and T2D as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the pathophysiology and renal and cardiovascular outcomes of mineralocorticoid receptor activation in chronic kidney disease in patients with type 2 diabetes
  • Evaluate the safety and efficacy evidence of the selective nonsteroidal mineralocorticoid receptor antagonist finerenone
  • Compare the clinical differences between steroidal and selective nonsteroidal mineralocorticoid receptor antagonists
  • Identify appropriate candidates for finerenone and strategies to implement use, including multidisciplinary care and overcoming clinical inertia

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-093-L01-P has been assigned to this live application-based activity (initial release date 3-20-22). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.